Trending >

Cronos Group has 67 per cent upside, GMP Securities says

Cronos Group

Despite the slower than expected rollout of recreational cannabis in Canada, analyst Martin Landry of GMP Securities is maintaining his “Buy” rating and $17.00 target price for Cronos Group (Cronos Group Stock Quote, Chart TSX, NASDAQ:CRON), which reports its third quarter financials on November 13.

From a distribution standpoint, the first two weeks of rec cannabis have been a bit of a bust, says Landry, who points to delays in shipments and the scant number of retail stores currently open across the country, where there are 12 in Quebec, 17 in Alberta, one in BC and none in Ontario.

Those realities, which also include industry-wide delays in receiving excise stamps, will impact Cronos’ Q3 and Q4 revenues, says Landry, who now calls for Q3 revenues of $3.6 million (was $11 million) and Q4 revenues of $10 million (was $21.6 million).

Nevertheless, Landry’s long-term forecast for CRON remains the same.

“Despite the possibility of near-term issues in the onset of the recreational market, our long-term forecasts remain unchanged. Between the ramp up of Building 4 and the Cronos GrowCo JV, we anticipate the company will have ample capacity in 2019,” Landry says in a client update on Monday.

“While we expect Cronos to have received its sales licence for Building 4, the company’s large 280,000 sq. ft. facility in Stayner, Ontario, the first harvest from Building 4 may have only occurred in November. In addition, with harvests being staggered, Cronos may have limited volumes available to supply the recreational market in Q4/18,” he says.


          This article is brought to you by

              PUF Ventures (CSE:PUF)

PUF Ventures is a biomedical ACMPR applicant with a production facility located in London, Ontario. PUF’s objective is to add shareholder value through cost efficient acquisitions, joint ventures and effective marketing while maintaining a lower risk profile through diversification and sound financial management.


   Click here to learn more about PUF Ventures




Landry now projects CRON to generate revenue and EBITDA in 2018 of $19.7 million (was $42.8 million) and negative $7.9 million (was $4.3 million), respectively. His estimates for 2019 remain unchanged at revenue of $160.7 million and EBITDA of $49.4 million.

At the time of publication, Landry’s $17.00 target represented a projected return of 67.2 per cent.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.
insta twitter facebook


Leave a Reply